alpha-MSH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
In June 2025, KFC temporarily closed all its 11 restaurants in Denmark and dismissed its franchise holder in the country, after a TV show (broadcast on June 23) revealed that in multiple restaurants, employees were systematically falsifying ("extending") use-by dates on raw chicken, and possibly other problems. Before broadcast, the questions by the TV reporter caused the national food authority to launch simultaneous inspection raids on all 11 restaurants. None got an all-clear, seven received strict warnings and four were given punishments (fines/charges or forced instant closure). Among the issues found by the authorities were moldy residue in multiple restaurants; a common procedure of reusing the breading mix continuously instead of using fresh breading mix every three hours, as stated in written procedures that were hastily changed during the raids (some inspections only saw the new procedure, which they found dubious); a common thawing procedure (with no written risk assessment documentation) for raw chicken which would allow chicken to be served up to four days after the start of defrosting and made it difficult to confirm the actual age of the raw chicken; and suspect messages between restaurant bosses and the national franchise holder about deceiving inspectors from both the government and KFC Western Europe.
=== Borderline personality disorder === A systematic review of psychopharmacology in borderline personality disorder identified clonidine as a promising adjunctive therapy targeting noradrenergic dysregulation, especially in comorbid PTSD cases. However, it emphasized the limitations of small sample sizes and called for larger placebo-controlled trials.
Thus, while there still is no cure for AIDS, there is great therapeutic and predictive benefit to identifying the virus and monitoring the virus levels within the blood of infected individuals, both for the patient and for the community at large.
Sources: en.wikipedia.org
Mahmoud Reza Banki (Persian: محمودرضا بانکی; born 1976) is an Iranian-American scientist, management consultant and business executive. Born in Tehran, Iran, Banki immigrated to the US to attend college and became a naturalized US citizen in the 1990s. In January 2010, Banki was arrested and charged with violating US sanctions against Iran by the United States Attorney's office in New York City. Ultimately Banki won his case on appeal, and it was permanently closed in July 2012. Banki spoke about his case at a TED Talk in 2014, presenting a case for change in criminal justice. As of 2015 a documentary film about the case was being made. In The Moth podcast released January 2017, Banki spoke to the personal toll of the ordeal. Banki has also spoken before various audiences for the cause of improving the criminal justice system. As of 2022, Banki was Chief Financial Officer and Chief Strategy Officer at leading streaming company Tubi. On January 20, 2021, Banki received a full and unconditional pardon from the President of the United States. He was the CFO of X Corp. between November 2024 and October 2025.
Numerous analogues and derivatives of DMT are known. Some examples include tryptamine (T), N-methyltryptamine (NMT), serotonin (5-hydroxytryptamine; 5-HT), psilocin (4-HO-DMT), psilocybin (4-PO-DMT), 4-AcO-DMT (psilacetin), 4-PrO-DMT, bufotenin (5-HO-DMT or N,N-dimethylserotonin), and 5-MeO-DMT (mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine (DPT), methylisopropyltryptamine (MiPT), diisopropyltryptamine (DiPT), methylallyltryptamine (MALT), diallyltryptamine (DALT), and pyr-T (N,N-tetramethylenetryptamine) and their derivatives. Some lesser-known DMT derivatives include 1-methyl-DMT, lespedamine (1-MeO-DMT), 2-methyl-DMT, 4-methyl-DMT, 4-MeO-DMT, 4-fluoro-DMT, 5-methyl-DMT, 5-ethyl-DMT, 5-TFM-DMT, 5-EtO-DMT, 5-TFMO-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 6-fluoro-DMT, 5,6-dibromo-DMT, 4,5-MDO-DMT, 4,5-DHP-DMT, 5,6-MDO-DMT, 5-MeS-DMT, 6-methyl-DMT, 6-HO-DMT, 6-MeO-DMT, 7-methyl-DMT, 7-MeO-DMT, NBoc-DMT (NB-DMT), α,N,N-TMT (α-Me-DMT), and α,N,N,O-TeMS (5-MeO-α-Me-DMT). Cyclized tryptamines containing DMT in their chemical structures include ibogalogs like ibogainalog and tabernanthalog; iboga alkaloids like ibogaine and noribogaine; lysergamides like ergine (LSA) and lysergic acid diethylamide (LSD); and partial ergolines and lysergamides like N-DEAOP-NMT, 10,11-seco-LSD, RU-28306 (4,α-methylene-DMT), RU-28251 (4,α-methylene-DPT), Bay R 1531 (LY-197206; 4,α-methylene-5-MeO-DPT), and NDTDI (8,10-seco-LSD), among others.
13 September Space - the Final Junkyard, about space debris; Nick Johnson of NASA; Paul Maley of United Space Alliance, and JSC Astronomical Society; Mark Mulrooney of the NASA Orbital Debris Observatory, and its liquid-mirror telescope; Scott J. Horowitz; Pam McCraw of Mission Operations Directorate at the Johnson Space Center in Texas; the Institute for Advanced Technology at the University of Texas at Austin; Richard Crowther of the Defence Evaluation and Research Agency; Don Kessler of NASA JSC; the French reconnaissance Cerise (satellite), which was damaged on 24 July 1996 by debris from Ariane; Darren McKnight and Kosmos 1275, launched on 4 June 1981, and was damaged on 24 July 1981; on 24 January 1978, the nuclear-powered Kosmos 954, a RORSAT, crashed into Canada; The Aerospace Corporation; the Russian Mars 96 was launched on 16 November 1996, to hopefully reach Mars on 12 September 1997, but re-entered the atmosphere east of Iquique in north Chile on 17 November 1997, carrying 270g of plutonium; as part of NASA's Systems for Nuclear Auxiliary Power, the satellite Transit 5BN-3 with a SNAP-9A nuclear power source, launched from Vandenberg Air Force Base (since May 2021, Vandenberg Space Force Base) in California, and never reached orbit on 21 April 1964, dispersing 1 kg of plutonium-238; the Iridium satellite constellation of 66 telecommunication satellites and the proposed Teledesic scheme; a damaged satellite could cause the catastrophic Kessler syndrome; John Muratore and the NASA X-38.
Sources: en.wikipedia.org
Lactiplantibacillus plantarum (formerly Lactobacillus arabinosus and Lactobacillus plantarum) is a widespread member of the genus Lactiplantibacillus and commonly found in many fermented food products as well as anaerobic plant matter. L. plantarum was first isolated from saliva. Based on its ability to temporarily persist in plants, the insect intestine and in the intestinal tract of vertebrate animals, it was designated as a nomadic organism. L. plantarum is Gram positive, bacilli shaped bacterium. L. plantarum cells are rods with rounded ends, straight, generally 0.9–1.2 μm wide and 3–8 μm long, occurring singly, in pairs or in short chains. L. plantarum has one of the largest genomes known among the lactic acid bacteria and is a very flexible and versatile species. It is estimated to grow between pH 3.4 and 8.8. Lactiplantibacillus plantarum can grow in the temperature range 12 °C to 40 °C. The viable counts of the "L. plantarum" stored at refrigerated condition (4 °C) remained high, while a considerable reduction in the counts was observed stored at room temperature (25 ± 1 °C).
Techniques such as the controlled encapsulation of individual gas bubbles to create hollow nanoparticles for synthesizing microbubbles with specific contents are vital for drug delivery systems. Both silica and titanium-based microparticles are used as durable shells after using gas to increase the flow velocity of the aqueous phase. A higher flow velocity allows greater control over the thickness of the aqueous shells. The emerging versatility of nanoparticles can be seen in the delivery of particle-loaded microdroplets being utilized in depot injections for drug delivery rather than the typical approach of injecting drugs intravenously. This is possible due to the low thickness of the shells which typically are in the range of 1 to 50 μm. More recent advancements in microfluidic particles allowed the synthesis of nanometer sized particles from biologically derived polymers. Using specific flow-focusing multiphase designs that control flow rate and temperature, the size of nanoparticle formation can be controlled along with the concentration and configuration of the droplets. Another technique for creating particle-loaded microdroplets is the use of lipid-hydrogel nanoparticles that can be manipulated into more narrowly shaped droplets, which is useful when soft or brittle materials must be used. These soft materials are especially important in the production of powders.
Recreational concentrations of ethanol are typically in the range of 1 to 50 mM. Very low concentrations of 1 to 2 mM ethanol produce zero or undetectable effects except in alcohol-naive individuals. Slightly higher levels of 5 to 10 mM, which are associated with light social drinking, produce measurable effects including changes in visual acuity, decreased anxiety, and modest behavioral disinhibition. Further higher levels of 15 to 20 mM result in a degree of sedation and motor incoordination that is contraindicated with the operation of motor vehicles. In jurisdictions in the U.S., maximum blood alcohol levels for legal driving are about 17 to 22 mM. In the upper range of recreational ethanol concentrations of 20 to 50 mM, depression of the central nervous system is more marked, with effects including complete drunkenness, profound sedation, amnesia, emesis, hypnosis, and eventually unconsciousness. Levels of ethanol above 50 mM are not typically experienced by normal individuals and hence are not usually physiologically relevant; however, such levels – ranging from 50 to 100 mM – may be experienced by alcoholics with high tolerance to ethanol. Concentrations above this range, specifically in the range of 100 to 200 mM, would cause death in all people except alcoholics. As drinking increases, people become sleepy or fall into a stupor. After a very high level of consumption, the respiratory system becomes depressed and the person will stop breathing.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.